Breakwater Capital Group Acquires Shares of 1,025 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Breakwater Capital Group bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,025 shares of the biopharmaceutical company's stock, valued at approximately $249,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 143 shares during the last quarter. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $71,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $0.44 during mid-day trading on Wednesday, hitting $280.70. 993,821 shares of the company traded hands, compared to its average volume of 882,395. The stock has a fifty day moving average price of $248.89 and a 200-day moving average price of $185.50. The stock has a market cap of $35.51 billion, a price-to-earnings ratio of -105.43 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $286.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the prior year, the company earned ($2.21) EPS. The firm's revenue was up 107.0% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at $20,563,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm's stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock worth $25,658,824 in the last quarter. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research analyst reports. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a report on Monday. UBS Group raised their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a "buy" rating in a report on Friday, June 28th. Barclays lifted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Finally, TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a "buy" rating in a research report on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $278.59.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.